
-
Marker Therapeutics NasdaqCM:MRKR Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia AND myelodysplastic syndromes; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.
Location: 2450 Holcombe Blvd, Houston, TX, 77021, United States | Website: https://markertherapeutics.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
-7.091M
Cash
19.19M
Avg Qtr Burn
-2.728M
Short % of Float
1.94%
Insider Ownership
9.33%
Institutional Own.
36.19%
Qtr Updated
12/31/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Neldaleucel/ MT-601 Details Non-Hodgkin lymphoma, Cancer | Phase 1 Data readout | |
Neldaleucel /MT-601 (w/ chemotherapy) Details Pancreatic cancer | Phase 1 Initiation | |
MT-401-OTS Details Acute myeloid leukemia | Phase 1 Initiation | |
MT-401 Details Acute myeloid leukemia | Failed Discontinued |